N/A
Completed N=3,141
Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
Source: ClinicalTrials.gov NCT01074255 ↗Enrolled (actual)
3,141
Serious AEs
2.8%
Results posted
Oct 2012
Primary outcomePrimary: Investigator Global Assessment of Participants' Response to Therapy With EMEND (Aprepitant) for the Prevention of Acute and Delayed Nausea Following Chemotherapy — 438; 2056; 446; 52 participants
Summary
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Investigator Global Assessment of Participants' Response to Therapy With EMEND (Aprepitant) for the Prevention of Acute and Delayed Nausea Following Chemotherapy |
438; 2056; 446; 52; 3 | — |
Eligibility Criteria
Inclusion Criteria
- Participants who are treated with EMEND for the first time as per the EMEND label
Exclusion Criteria
- Contraindication to EMEND
Data sourced from ClinicalTrials.gov (NCT01074255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.